Io Biotech, INC 8-K filings

IO Biotech, Inc. has ceased operations and filed a voluntary petition for Chapter 7 bankruptcy, leading to the resignation of its board and termination of all employees.

IO Biotech, Inc. received a Nasdaq notice for failing to meet the minimum $50 million market value of listed securities requirement.

IO Biotech announced a significant workforce reduction and engaged Raymond James as a financial advisor to explore strategic alternatives.

IO Biotech announced it is exploring strategic alternatives, including a potential merger, sale of assets, or liquidation, to maximize stockholder value.

IO Biotech, Inc. received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, initiating a 180-day compliance period.

IO Biotech, Inc. announced the resignation of its Senior Vice President and Chief Accounting Officer, Brian Burkavage, and the appointment of Chief Financial Officer Amy Sullivan to the role.

IO Biotech presented updated clinical data for its Cylembio drug candidate at the Jefferies Global Healthcare Conference, highlighting promising Phase 3 results in advanced melanoma and outlining plans for future trials and regulatory submissions.

IO Biotech reported third quarter 2025 financial results and business highlights, including a narrowly missed primary endpoint in its Phase 3 advanced melanoma trial and a reduced cash runway.

IO Biotech announced the FDA recommended against a Biologics License Application for Cylembio based on IOB-013 trial data, leading to a 50% workforce reduction and a new registrational study plan.

IO Biotech announced its Cylembio Phase 3 trial for advanced melanoma narrowly missed statistical significance for progression-free survival, while reporting Q2 2025 financial results and extending cash runway into Q1 2026.

IO Biotech announced Phase 3 trial results for Cylembio in advanced melanoma, showing clinical improvement in progression-free survival but narrowly missing statistical significance on the primary endpoint.

IO Biotech, Inc. has announced the drawdown of a €12.5 million second tranche from its European Investment Bank loan facility, accompanied by the issuance of warrants for over 4.2 million common shares.

IO Biotech, Inc. has updated its CEO's service agreement to provide enhanced severance benefits in the event of a termination without cause or for good reason, particularly around a change in control.

IO Biotech, Inc. announced the results of its 2025 Annual Meeting of Stockholders, where David Smith was elected as a Class I Director and EY Godkendt Revisionspartnerselskab was ratified as the independent registered public accounting firm.

IO Biotech, Inc. announced it has successfully regained compliance with Nasdaq's minimum bid price requirement, closing the previously reported listing deficiency.

IO Biotech announced its Q1 2025 financial results, highlighting the continued progress of its Phase 3 trial for Cylembio and its recognition as a top innovative biotech company.

IO Biotech has drawn down a $10 million tranche from its financing agreement with the European Investment Bank (EIB) and issued warrants to purchase common stock in connection with the loan.

IO Biotech reports business highlights for Q4 2024, including updates on Cylembio's clinical trials and cash position.

IO Biotech has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing its listing status at risk.

IO Biotech has secured a debt financing agreement with the European Investment Bank for up to $57.5 million to advance its therapeutic cancer vaccine programs.

IO Biotech has adopted amended and restated bylaws, effective immediately, revising procedures for stockholder nominations, proposals, and meeting conduct.

IO Biotech announced positive progress in its clinical trials for its cancer vaccine, IO102-IO103, and reported its third quarter 2024 financial results, with a cash runway expected to last into the fourth quarter of 2025.

IO Biotech's Phase 3 trial of IO102-IO103 in combination with KEYTRUDA for advanced melanoma will continue without modifications after a positive interim analysis by the Independent Data Monitoring Committee.

IO Biotech reported its second quarter 2024 financial results and provided an update on its clinical trials, including the expected interim analysis of its Phase 3 melanoma trial in Q3 2024.

IO Biotech held its 2024 Annual Meeting of Stockholders, electing three Class III directors and ratifying its independent accounting firm.

IO Biotech reported its first quarter 2024 financial results, provided updates on its clinical trials, and strengthened its executive team.

IO Biotech announces the resignation of board member Jack Nielsen, effective April 24, 2024, due to health reasons.

IO Biotech announced the completion of enrollment in its Phase 3 trial for its lead cancer vaccine, IO102-IO103, and provided updates on its financial results and other clinical programs.